Nexus Medical Labs Receives FDA Emergency Use Authorization for SARS-CoV-2 Test Using the RHINOstic™ Automated Nasal Swab from Rhinostics

Automated and Easily Scalable Swab-Based Workflow Supports Increased Sample Throughput and Processing Consistency

Excerpt from the Press Release:

WALTHAM, Mass. & WATERTOWN, Mass.–(BUSINESS WIRE)–Rhinostics Inc. and Nexus Medical Labs recently received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test enabling unsupervised self-collection. The test, based on a workflow originally developed by Harvard University, relies on high throughput lab automation and use of the RHINOstic™ Automated Nasal Swab from Rhinostics.

“This EUA approval is an acknowledgment that we have developed and validated a high quality, cost-effective and rapid turnaround test. Our clients are now able to offer ultra-rapid and high-quality testing services that translates into same-day and reliable service at a better value,” said Rob Miller, Co-Founder and CEO at Nexus.

Nexus specializes in offering improved access to laboratory testing to telehealth, partner laboratories, and other clients, processing medically and self-collected samples in its CLIA-certified laboratory. The facility has been outfitted with the automated RHINOstic™ swab workflow to process COVID-19 and other swab-based tests, with capacity that can scale to tens of thousands per day. High throughput processing facilitates turnaround times as low as 4 hours.

“We look forward to expanding our offering to a broad array of telehealth providers, partner laboratories, companies, schools, and associations that seek to ensure the health of their respective legions. Making affordable quality lab testing more accessible is a core part of our mission,” says Brandon Johnson, Co-Founder and Managing Director at Nexus.

Click the button below to read the entire Press Release:

Continue Reading The Press Release